- Home
- SILC vs AGEN Comparison
SILC vs AGEN Comparison
Compare SILC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- AGEN
- Stock Information
- Founded
- SILC 1987
- AGEN 1994
- Country
- SILC Israel
- AGEN United States
- Employees
- SILC N/A
- AGEN N/A
- Industry
- SILC Computer Manufacturing
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SILC Technology
- AGEN Health Care
- Exchange
- SILC Nasdaq
- AGEN Nasdaq
- Market Cap
- SILC 85.1M
- AGEN 87.7M
- IPO Year
- SILC 1994
- AGEN 2000
- Fundamental
- Price
- SILC $15.25
- AGEN $7.27
- Analyst Decision
- SILC Hold
- AGEN Buy
- Analyst Count
- SILC 2
- AGEN 4
- Target Price
- SILC N/A
- AGEN $13.00
- AVG Volume (30 Days)
- SILC 12.6K
- AGEN 1.4M
- Earning Date
- SILC 07-31-2025
- AGEN 08-07-2025
- Dividend Yield
- SILC N/A
- AGEN N/A
- EPS Growth
- SILC N/A
- AGEN N/A
- EPS
- SILC N/A
- AGEN N/A
- Revenue
- SILC $58,134,000.00
- AGEN $99,524,000.00
- Revenue This Year
- SILC $6.26
- AGEN $12.69
- Revenue Next Year
- SILC $19.14
- AGEN N/A
- P/E Ratio
- SILC N/A
- AGEN N/A
- Revenue Growth
- SILC N/A
- AGEN N/A
- 52 Week Low
- SILC $11.35
- AGEN $1.38
- 52 Week High
- SILC $18.24
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- SILC 54.04
- AGEN 68.42
- Support Level
- SILC $14.93
- AGEN $4.78
- Resistance Level
- SILC $15.97
- AGEN $6.20
- Average True Range (ATR)
- SILC 0.57
- AGEN 0.62
- MACD
- SILC -0.00
- AGEN 0.10
- Stochastic Oscillator
- SILC 56.96
- AGEN 98.90
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).